Sign in
Taking people in United StatesPhase 2

Tests NMN in adults with type 2 diabetes and diabetic kidney disease

Tests whether NMN, compared with placebo, helps kidney damage in adults with diabetes.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
NAD Augmentation in Diabetes Kidney Disease
Status
Recruiting
Phase
Phase 2
People taking part
156 people, planned
Started
13 Apr 2023
Expected to end
31 Mar 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Investigational Product - MIB 626
  • Placebo
Record updated
13 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and postmenopausal women aged 30 or older who have type 1 or type 2 diabetes and kidney disease with protein in the urine.

Age
30 years or older
Sex
Men and postmenopausal women (periods stopped for one year or more, and/or FSH > 20 U/L)
Disease stage
Type 1 or type 2 diabetes with kidney disease: urine albumin-to-creatinine ratio (UACR) of at least 60 mg/g creatinine on average, and eGFR > 25 mL/min/1.73 m2. HbA1c must be below 10% (86 mmol/mol).
Earlier treatment
People with type 2 diabetes and UACR > 300 mg/g creatinine must already be taking an ACE inhibitor, an ARB or an SGLT2 inhibitor.
Biomarker or test result
Diabetes shown by HbA1c > 6.4% (46 mmol/mol) or two fasting glucose results > 125 mg/dL (6.9 mmol/L), or by self-report or medical record plus a diabetes medicine. Average of two morning UACR results at 100 mg/g creatinine or above.

Main reasons for not taking part

  • UACR above 5,000 mg/g creatinine, or eGFR below 25
  • AST or ALT more than 3 times the upper limit of normal
  • Major heart or blood vessel event in the past 3 months
  • Pregnant or planning pregnancy in the next 6 months
  • Past severe allergic reaction (anaphylaxis) to vitamin B3 derivatives

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH > 20 U/L), 30 years or older
  • Has type 1 or type 2 diabetes mellitus, as indicated by any of the following:; Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication; ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record; HbA1c >6.4%; or 2 fasting glucose > 125 mg/dL
  • Has an average of two or more morning UACR equal to or above 100mg/g creatinine each of which must be equal to or greater than 60 mg / g creatinine with at least one UACR value measured during the screening visit; Recent UACR value in the medical record within the preceding 3 months prior to screening is acceptable
  • If type 2 diabetic and UACR is > 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB or a SGLT2 inhibitor
  • eGFR > 25 mL/ min / 1.73 m2
  • Hemoglobin A1c <10%
  • Able to speak English or Spanish or Haitian Creole
  • Willing and able to provide written informed consent
  • In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months

Who cannot take part

  • Current alcohol or substance use disorder or dependence (DSM 5 criteria)
  • Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures
  • An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month
  • Has a history of anaphylaxis from vitamin B3 derivatives
  • If patient has a confirmed diagnosis of type 3 diabetes, or gestational diabetes
  • Fasting morning UACR > 5,000 mg/ g creatinine
  • Other laboratory abnormalities:; Has AST or ALT > 3 times the upper limit of normal; eGFR < 25 mL/ min / 1.73 m2; Hematocrit < 0.34 or > 0.50 L/L
  • A major adverse cardiovascular event in preceding 3 months
  • Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
  • BMI > 42.5 kg/ m2

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Nancy K Latham, PhDTaking people

About the trial

What the trial wants to find out

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

The 2 groups in the trial

  • Investigational Product - MIB 626Existing treatment, for comparison

    The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

  • PlaceboPlacebo, for comparison

    Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
NAD Augmentation to Treat Diabetes Kidney Disease: A Randomized Controlled Trial
Plain-language title
Tests NMN in adults with type 2 diabetes and diabetic kidney diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
13 April 2026